Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.
Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F, Cantonetti M, Stelitano C, Feldman T, Gavarotti P, Sorasio R, Mulè A, Leone M, Rambaldi A, Biggi A, Barrington S, Fallanca F, Ficola U, Chauvie S, Gianni AM; Gruppo Italiano Terapie Innovative nei Linfomi (GITIL). Gallamini A, et al. Among authors: sorasio r. Br J Haematol. 2011 Mar;152(5):551-60. doi: 10.1111/j.1365-2141.2010.08485.x. Epub 2010 Dec 20. Br J Haematol. 2011. PMID: 21166786 Free article. Clinical Trial.
Peripheral blood CD34+ percentage at hematological recovery after chemotherapy is a good early predictor of harvest: a single-center experience.
Sorasio R, Bonferroni M, Grasso M, Strola G, Rapezzi D, Marenchino D, Di Marco C, Castellino C, Mattei D, Mordini N, Fiore F, Celeghini I, Borra A, Ghiglia A, Gallamini A. Sorasio R, et al. Biol Blood Marrow Transplant. 2014 May;20(5):717-23. doi: 10.1016/j.bbmt.2014.02.002. Epub 2014 Feb 11. Biol Blood Marrow Transplant. 2014. PMID: 24525280 Free article. Clinical Trial.
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM. Guidetti A, et al. Among authors: sorasio r. Clin Cancer Res. 2014 Nov 15;20(22):5641-51. doi: 10.1158/1078-0432.CCR-14-0770. Epub 2014 Sep 19. Clin Cancer Res. 2014. PMID: 25239609 Clinical Trial.
Relapsing/refractory HL after autotransplantation: which treatment?
Di Renzo N, Gaudio F, Carlo Stella C, Oppi S, Pelosini M, Sorasio R, Stelitano C, Rigacci L. Di Renzo N, et al. Among authors: sorasio r. Acta Biomed. 2020 May 25;91(S-5):30-40. doi: 10.23750/abm.v91iS-5.9912. Acta Biomed. 2020. PMID: 32525132 Free PMC article.
Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy.
Viviani S, Mazzocchi A, Pavoni C, Taverna F, Rossi A, Patti C, Romano A, Trentin L, Sorasio R, Guidetti A, Gottardi D, Tarella C, Cimminiello M, Zanotti R, Farina L, Ferreri AJM, Galbiati M, Corradini P, Gianni AM, Gallamini A, Rambaldi A. Viviani S, et al. Among authors: sorasio r. Hematol Oncol. 2020 Oct;38(4):501-508. doi: 10.1002/hon.2775. Epub 2020 Jul 30. Hematol Oncol. 2020. PMID: 32602970
Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial.
Gallamini A, Rossi A, Patti C, Picardi M, Romano A, Cantonetti M, Oppi S, Viviani S, Bolis S, Trentin L, Gini G, Battistini R, Chauvie S, Sorasio R, Pavoni C, Zanotti R, Cimminiello M, Schiavotto C, Viero P, Mulé A, Fallanca F, Ficola U, Tarella C, Guerra L, Rambaldi A. Gallamini A, et al. Among authors: sorasio r. J Clin Oncol. 2020 Nov 20;38(33):3905-3913. doi: 10.1200/JCO.20.00935. Epub 2020 Sep 18. J Clin Oncol. 2020. PMID: 32946355 Clinical Trial.
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
Santoro A, Mazza R, Spina M, Califano C, Specchia G, Carella M, Consoli U, Palombi F, Musso M, Pulsoni A, Kovalchuk S, Bonfichi M, Ricci F, Fabbri A, Liberati AM, Rodari M, Giordano L, Chimienti E, Balzarotti M, Sorasio R, Gallamini A, Ghiggi C, Ciammella P, Ricardi U, Chauvie S, Carlo-Stella C, Merli F. Santoro A, et al. Among authors: sorasio r. Ann Hematol. 2021 Oct;100(10):2547-2556. doi: 10.1007/s00277-021-04604-x. Epub 2021 Jul 30. Ann Hematol. 2021. PMID: 34327561 Clinical Trial.
Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial.
Biggi A, Chauvie S, Fallanca F, Guerra L, Bergesio F, Menga M, Bianchi A, Gregianin M, Chiaravalloti A, Schillaci O, Pavoni C, Patti C, Picardi M, Romano A, Schiavotto C, Sorasio R, Viviani S, La Nasa G, Trentin L, Rambaldi A, Gallamini A. Biggi A, et al. Among authors: sorasio r. Hematol Oncol. 2023 Aug;41(3):415-423. doi: 10.1002/hon.3117. Epub 2023 Jan 4. Hematol Oncol. 2023. PMID: 36534947 Clinical Trial.
High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies.
Viviani S, Vanazzi A, Frassoni S, Rusconi C, Rossi A, Romano A, Patti C, Schiavotto C, Sorasio R, Marasco V, Lissandrini L, Rapezzi D, Gottardi D, Cocito F, Mulè A, Leotta S, Gini G, Sorio M, Derenzini E, Rambaldi A, Bagnardi V, Tarella C. Viviani S, et al. Among authors: sorasio r. Leuk Lymphoma. 2024 Apr;65(4):460-471. doi: 10.1080/10428194.2023.2298273. Epub 2024 Jan 2. Leuk Lymphoma. 2024. PMID: 38164812
38 results